BECTON DICKINSON AND CO
BDXNYSETrading Snapshot
- Day Range
- $193.80 β $196.88
- 52-Week Range
- $127.59 β $200.47
- Volume (shares)
- 1,740,440
- Avg Volume (shares)
- β
- Shares Outstanding
- 272.4M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $21.84B
- Last Q Revenue
- $4.98B
- P/E Ratio
- 58.8
- P/S Ratio
- 2.6x
- EPS (TTM)
- $3.42
- Dividend Yield
- 2.04%
- Dilution (1yr)
- β1.8%
BECTON DICKINSON AND CO
BDXAbout BECTON DICKINSON AND CO
Operating globally, Becton, Dickinson and Company (BD) is a prominent enterprise focused on the development, manufacturing, and distribution of a broad spectrum of medical technology. This includes essential medical supplies, sophisticated devices, advanced laboratory equipment, and critical diagnostic products. Its extensive customer base comprises healthcare providers, clinical institutions, medical researchers, pharmaceutical firms, and the general public around the world. The BD Medical division delivers a comprehensive suite of products primarily focused on medication management and drug delivery. This encompasses a variety of intravenous (IV) access solutions, such as peripheral and advanced catheters, central lines, acute dialysis catheters, and related vascular care items including needle-free connectors and closed-system drug transfer devices. It also provides essential injection equipment like hypodermic syringes, needles, anesthesia trays, enteral syringes, and sharps disposal systems. Additionally, this segment develops integrated systems for IV medication and infusion therapy, medication compounding workflow, automated dispensing, and supply chain optimization. Specialized products for diabetes management, including pen needles, along with prefillable drug delivery systems, are also key offerings. BD Life Sciences focuses on diagnostic and research tools, offering products for specimen and blood collection. This segment supplies automated systems for culturing blood and tuberculosis, molecular testing, microorganism identification, and drug susceptibility analysis. It also provides liquid-based cytology systems, rapid diagnostic assays, microbiology laboratory automation, and plated media. Furthermore, it offers advanced solutions for cell analysis, including fluorescence-activated cell sorters and analyzers, antibodies, kits, and reagent systems. These are crucial for single-cell gene expression analysis, as well as for clinical oncology, immunological, and transplantation diagnostics and monitoring. Finally, the BD Interventional segment delivers specialized products for surgical and interventional procedures. Its portfolio includes solutions for hernia and soft tissue repair, biological and bioresorbable grafts, and biosurgery, alongside other surgical products. This segment also addresses surgical infection prevention, provides a range of surgical and laparoscopic instrumentation, offers peripheral intervention products, and supplies urology and critical care devices. Established in 1897, the company maintains its headquarters in Franklin Lakes, New Jersey.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates

BD Advances Portal Hypertension Care in the U.S. with Support for More Personalized Treatment Options
The launch of theΒ Livertyβ’ TIPS Stent Graft gives physicians flexibility to tailor treatment for patients. FRANKLIN LAKES, N.J.

Citizens Financial Group Inc. RI Purchases 4,390 Shares of Becton, Dickinson and Company $BDX
Citizens Financial Group Inc. RI increased its position in shares of Becton, Dickinson and Company (NYSE: BDX) by 129.5% during the undefined quarter, according to its most recent filing with the Securities and Exchange

First Eagle Global Fund Q3 202 Portfolio Update
Global Fund A Shares (without sales charge) posted a return of 2.10% in third quarter 2026. Leading contributors in the First Eagle Global Fund this quarter included Workday, Inc. Class A, Meta Platforms, Inc. Class A, S

First Eagle U.S. Value Fund Q3 2026 Portfolio Review
U.S. Fund A Shares (without sales charge) posted a return of 4.36% in third-quarter 2026. The US Fund outperformed the S&P 500 Index in the period. Shares of Meta performed well following the strong reception of Muse, it

Best Dividend Kings: October 2026
Dividend Kings have outperformed SPY YTD, rising 13.5% versus SPY's 12.32%, with a strong October rebound. Twenty-six Dividend Kings appear both potentially undervalued and offer long-term annualized expected returns of

The Dividend Aristocrats Ranked By Quality Scores (October 2026)
I rank all 69 S&P 500 Dividend Aristocrats by my 9F Quality Scores, segmenting them into undervalued, fairly valued, and overvalued groups. My consensus fair value estimates, blending up to 40 data points per stock, high